Let's check out two exciting biotech stocks that may climb 58% and 200%, according to Wall Street. Image source: Getty Images ...

A team of scientists has developed a cutting-edge CRISPR system that can not only combat antibiotic resistance but actively reverse it. This breakthrough could change the course of modern medicine, ...

CRISPR Therapeutics' CASGEVY gene-editing therapy targets severe SCD and TDT. Click here to read why CRSP stock is rated as a Buy.

CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings on Feb. 13. At first glance, that may seem contradictory. The company ...

Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...

Nikki Romanik and Ashish K Jha propose a new surveillance system to detect and attribute emerging biological threats to enable a rapid public health response Recent advances in bioengineering ...

Researchers engineered lipid nanoparticles to deliver a full CFTR gene into human airway cells, restoring near-normal ...

Morningstar released its Q1 2026 U.S. Stock Market Outlook report last month. Led by Chief U.S. Economist Preston Caldwell ...

Rather than spraying more chemicals, Resurrect Bio is rebuilding crops’ immune systems to help them fight disease naturally.

It already exists in the natural world. Now, thanks to breakthroughs in genetic engineering, scientists have created “supersilk.” And it’s poised to upgrade far more than our clothing.

Emerging technologies, increasing focus on R&D, and a growing demand in treating previously incurable diseases present significant opportunities across diverse applications and regions Cell & Gene ...

Learn more about whether IDEAYA Biosciences, Inc. or Viridian Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.